Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Guaifenesin Ban Justified By Compliance Policy Guide – Adams Labs

This article was originally published in The Tan Sheet

Executive Summary

FDA should notify federal agencies that Rx single-ingredient, extended-release guaifenesin drugs are no longer available for contract purchase, Mucinex marketer Adams Labs says in Nov. 22 comments
Advertisement

Related Content

FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition
Adams Mucinex Approval Spurs FDA Crackdown On Guaifenesin Products
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals

Topics

Advertisement
UsernamePublicRestriction

Register

PS094946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel